Testing higher-dose ivermectin for COVID-19
Treatments studied
Part of Infections clinical trials.
This trial studies whether a higher dose of ivermectin helps people with COVID-19. It looks at how well the treatment works and whether it causes side effects for participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You currently have COVID-19
- You do not have an allergy to ivermectin
- You have not had serious side effects from ivermectin in the past
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies new drug treatment plans for people who currently have COVID-19. If it works better than standard care, it could improve recovery for patients.
This trial tests if adding ivermectin, a common anti-parasitic drug, to standard immunotherapy (checkpoint inhibitors) can help fight solid tumors. You may be eligible if you are already on immunotherapy for at least 21 days and have a stable or manageable cancer.
This early-stage study tests COVID-19 treatments in people who have recently developed symptoms and who test positive for the virus. It aims to find safer, more effective options for preventing worsening disease, especially in higher-risk groups.
This trial tests an investigational medicine called ibuzatrelvir for adults with COVID-19 who have a weakened immune system. The study aims to see if it helps them recover and avoid severe illness.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
This trial tests if a new medicine called ibuzatrelvir can help people with COVID-19 who have certain health risks avoid severe illness. It is for patients who cannot or choose not to take another COVID-19 pill called Paxlovid.
Hear when a new COVID trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.